Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Looking Forward to Pharma's Decade of Predictive Efficacy

This article was originally published in Start Up

Executive Summary

Drug developers can now tap into an array of new preclinical technologies including some that give them the ability to interrogate compounds in a broad biological context-a systems biology approach. In this issue, we profile four start-ups with technologies designed to predict drugs' efficacy: Champions Biotechnology, Cytox, Immuneering and Rhenovia.

You may also be interested in...



BioLeap LLC

BioLeap LLC hopes to be part of the solution to Big Pharma's pipeline problem. Its computational technology for identifying and optimizing lead compounds focuses on the free energy of binding, which represents an enormous computational problem. But the developers of BioLeap's technology have created an industrial process that makes such calculations feasible in a reasonably fast time frame.

Start-Up Previews (09/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Looking Forward to Pharma's Decade of Predictive Efficacy," features profiles of Champions Biotechnology, Cytox, Immuneering and Rhenovia. Plus these Start-Ups Across Health Care: Freedom Meditech, MedShape Solutions, Molteni Therapeutics and TARIS Biomedical.

Champions Biotechnology Inc.

Champions Biotechnology Inc.'s preclinical screening technology uses xenografts that it creates by implanting primary human cancer tumors into immune-deficient mice. The tumor cells are never passaged in cell tissue culture and therefore maintain the fundamental genotypic features of the original cancer because the risk of mutations through successive generations in culture is eliminated. The company has signed preclinical screening deals with a number of partners and it's also building its own therapeutic pipeline.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091845

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel